Zobrazeno 1 - 3
of 3
pro vyhledávání: '"M. B. Degterev"'
Autor:
E. O. Goloshchapova, O. B. Rounova, A. S. Minero, O. V. Fadeikina, R. A. Volkova, M. B. Degterev, S. A. Taran, R. R. Shukurov, O. B. Ustinnikova
Publikováno v:
Биопрепараты: Профилактика, диагностика, лечение, Vol 22, Iss 1, Pp 23-37 (2022)
Medicines based on recombinant human interferons (rhIFNs) beta-1a and beta-1b are used as first-line treatment of multiple sclerosis. Meanwhile, rhIFN beta-1a and beta-1b have structural differences associated with the eukaryotic or prokaryotic expre
Externí odkaz:
https://doaj.org/article/e581ec390f4d49fa85d1caf3eb2d062f
Autor:
M. B. Degterev, R. R. Shukurov
Publikováno v:
Тонкие химические технологии, Vol 16, Iss 1, Pp 76-87 (2021)
Objectives. In this biosimilar research, we compare the monoclonal antibody eculizumab obtained from different drugs [original Soliris® (Alexion Pharmaceuticals) and candidate Elizaria® (Generium)] by intact mass measurement and middle-up mass spec
Externí odkaz:
https://doaj.org/article/22bab6db8fc24fed806631dff24d4c1b
Autor:
R. R. Shukurov, M. B. Degterev
Publikováno v:
Тонкие химические технологии, Vol 16, Iss 1, Pp 76-87 (2021)
Objectives. In this biosimilar research, we compare the monoclonal antibody eculizumab obtained from different drugs [original Soliris® (Alexion Pharmaceuticals) and candidate Elizaria® (Generium)] by intact mass measurement and middle-up mass spec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02b27e92df0ba69392989655856e261a
https://doi.org/10.32362/2410-6593-2021-16-1-76-87
https://doi.org/10.32362/2410-6593-2021-16-1-76-87